← boardnext 2027-03
PEPG
PepGen Incdistress 6/10 · elevated risk$1.920%today-73% from 52w high
Rare / Genetic 2
Lead: Duchenne muscular dystrophy · est. market ~$4B (approx, global)
Revenue
pre-revenue
Liquidity
$132M
Runway
1.7 yrs
Shares 1y
+111%
Price & events
-65.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-14.7%
1W
+5.5%
1M
+20.8%
3M
-64.8%
6M
+31.5%
1Y
-89.1%
2Y
—
5Y
-85.1%
All
Overview
- Market Cap
- $132.80M
- Volume
- 66.99K
- 52 Week Range
- $1.01 – $7.17
- Total Shares
- 69.17M
- Float Shares
- 36.05M
- Short %
- 8.17%
- % Held by Insiders
- 0.23%
- % Held by Institutions
- 88.37%
- RVOL
- 0.07x
- Beta
- 1.88
Pipeline stages · 2 programs
PGN-EDODM1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IV infusion
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | PGN-EDODM1orphanrare pediatricfast track | Myotonic Dystrophy 1 | — | recruiting |
| 2029-01 Estimated 50% readout ~2029-02-15 | Phase 2 | PGN-EDODM1orphanrare pediatricfast track | Myotonic Dystrophy 1 | — | recruiting |
| 2025-10-28 | Phase 1 | PGN-EDODM1 for infusionorphanrare pediatricfast track | Myotonic Dystrophy 1 | 24 | completed |
| 2025-08-28 | Phase 2 | PGN-EDO51orphanrare pediatricfast track | Duchenne Muscular Dystrophy | 7 | terminated |
| 2025-05-28 | Phase 2 | IV infusion | Duchenne Muscular Dystrophy (DMD) | 0 | withdrawn |
Catalyst news & presentations · 14
- 2027Guided 40%readoutPhase 2PGN-EDODM1 · FREEDOM2 12.5 mg/kg clinical resultsSEC 8-K
- H2 2026Guided 55%readoutPhase 2PGN-EDODM1 · FREEDOM2 10 mg/kg clinical resultsSEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- first quarter of 2026trial initiationsecondaryPhase 2PGN-EDODM1 · Initiation of 10 mg/kg dose cohort in FREEDOM2 MAD studySEC 8-K
- first quarter of 2026readoutPhase 2PGN-EDODM1 · Results from 5 mg/kg cohort of FREEDOM2-DM1SEC 8-K
- 2026-03-04clinical holdPGN-EDODM1 · FDA placed partial clinical hold on FREEDOM2-DM1 Phase 2 trial due to questions on preclinical studies; no issues with Phase 1 clinical dataSEC 8-K
- during 2025readoutPhase 2PGN-EDO51 · Update on status of CONNECT2 trialSEC 8-K
- third quarter of 2025readoutPhase 2PGN-EDO51 · Results from 10 mg/kg cohort of CONNECT1-EDO51SEC 8-K
- 2025-05-28trial discontinuedPGN-EDO51 · Company discontinues development of PGN-EDO51 and wind down all DMD-related activities.SEC 8-K
- early 2025readoutPhase 2PGN-EDO51 · Report initial results from 10 mg/kg cohort.SEC 8-K
- 2025-03-04enrollment delayPGN-EDO51 · Voluntary temporary pause of CONNECT2-EDO51 studySEC 8-K
- by year-endtrial initiationsecondaryPhase 2PGN-EDO51 · Open CONNECT2 trial in the United States.SEC 8-K
- 2024-12-16clinical holdPGN-EDO51 · FDA clinical hold on IND for CONNECT2-EDO51 Phase 2 trial in DMDSEC 8-K
- October 11th at 2:15-3:15pm CESTconferencedata presentationsecondaryPGN-EDODM1 · Nonclinical data for PGN-EDODM1 demonstrated nuclear delivery and activitySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $10 (+434% upside) · 8 analysts
- 2026-06-16Craig-HallumBuy
- 2026-05-13WedbushOutperform
- 2026-04-01WedbushOutperform
- 2026-03-31WedbushOutperform
- 2026-02-25OppenheimerOutperform
- 2026-02-18GuggenheimBuy
Competitors — Duchenne muscular dystrophy
- EWTXEdgewise Therapeutics, Inc.$4.1B · D4
- DYNDyne Therapeutics, Inc.$3.3B · D4
- SRPTSarepta Therapeutics, Inc.$1.6B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CAPRCAPRICOR THERAPEUTICS, INC.$1.1B · D4
- SLDBSolid Biosciences Inc.$777M · D4
- RGNXREGENXBIO Inc.$508M · D7
- TRDAEntrada Therapeutics, Inc.$236M · D2
- DTILPRECISION BIOSCIENCES INC$185M · D6
- CPIXCUMBERLAND PHARMACEUTICALS INC$102M · D0
Recent news
- 2026-07-16Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today - Stocktwits
- 2026-07-14PepGen (PEPG) Edges Lower, Holding Near Key Support Zone - Put Flow Alert - dars.gov.et
- 2026-07-12PepGen Inc. (PEPG) Edges Higher as Stock Holds Above Key Support - Volume Weighted Price - dars.gov.et
- 2026-07-10PepGen Q1 2026 Earnings: Narrower-than-Expected Loss Drives Shares Higher - Post-Announcement Reaction - dars.gov.et
- 2026-07-09$PEPG stock is up 15% today. Here's what we see in our data. - Quiver Quantitative
- 2026-07-09PepGen Q1 2026 Earnings: Narrower-than-Expected Loss Drives Shares Higher - Debt Analysis Report - dars.gov.et
- 2026-07-08PepGen Inc. (PEPG) Q1 2026 Earnings: Narrower-than-expected loss drives positive stock reaction - Earnings Cycle Report - dars.gov.et
- 2026-07-08PepGen Inc. (PEPG) Q1 2026 Earnings: Narrower-than-expected loss drives positive stock reaction - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.